Sequenom this week announced three new hires to support the genetic service business it launched in October.
Jeffrey Otto has been hired as the company's director of genetic services. Prior to joining Sequenom, Otto held several positions at Genaissance Pharmaceuticals, most recently as director of business development. Before his Genaissance positions, Otto was an assistant professor and principal investigator at the Rush-Presbyterian Department of Orthopedic Surgery-St. Luke's Medical Center. Otto earned an MBA from the Ellis College of the New York Institute of Technology, and a PhD in biology from Marquette University.
Min Seob Lee joins Sequenom as manager of genetic services. Lee conducted a post-doctoral fellowship at the Beth Israel Deaconess Medical Center of Harvard Medical School, and he received a PhD in biological science from the City of Hope National Medical Center and Beckman Research Institute.
The company appointed Donald Benson as national account manager for genetic services. Benson's experience includes positions at Bios Corporation, Boehringer Mannheim Biochemicals, Eppendorf North America, Genaissance, Orchid Biosciences, Qiagen, and Protein-DNA Imageware. Benson holds a BS from Rutgers University.
Gregory Schiffman has been added to Nanomix's board of directors, the nanotechnology company said this week. He has also been appointed chairperson of Nanomix's audit committee.
Schiffman is currently the executive vice president and chief financial officer of Affymetrix. He joined Affymetrix in 2001 from Applied Biosystems where he held the position of vice president, controller. He also has experience in finance, manufacturing and distribution management from his prior tenure with Hewlett Packard and IBM.
Schiffman holds a BSc from DePaul University and an MBA from Northwestern University.
Exiqon this week announced the launch of its miRCURY Arrays for profiling of miRNAs in human, mouse, and rat.
The Copenhagen, Denmark-based company also launched its miRCURY Array Labeling kit for direct labeling of miRNAs from total RNA. Products are available worldwide directly from Exiqon.
Exiqon said that the miRCURY Array product enables miRNA expression profiling in samples of down to 1µg of labeled total RNA and uses the firm's high-affinity nucleotide analogue locked nucleic acid technology to enhance hybridization.
The National Institutes of Health announced last week that it is seeking licensees for two array-related technologies.
The first, Methods for Manipulating Nucleic Acids, provides methods for amplifying nucleic acid templates from small samples. The nucleic acid templates amplified by the disclosed methods can be used in combination with any method and can be labeled with any labeling method, the NIH said.
The second available technology, Amine Modified Random Primers for Microarray Detection, provides a method for labeling nucleic acid molecules for use in hybridization reactions, and kits employing these methods. According to the NIH, the fluorescence-labeled cDNA probes for DNA microarray studies also use less input RNA.
Those interested should contact NIH's Office of Technology Transfer at (301) 435 4507.